Y Intercept Hong Kong Ltd Sells 11,622 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Y Intercept Hong Kong Ltd cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 47.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,699 shares of the specialty pharmaceutical company’s stock after selling 11,622 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Jazz Pharmaceuticals were worth $1,415,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in JAZZ. XTX Topco Ltd raised its position in Jazz Pharmaceuticals by 57.5% during the third quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock valued at $1,296,000 after purchasing an additional 4,245 shares during the period. Krensavage Asset Management LLC raised its holdings in Jazz Pharmaceuticals by 1.1% during the 3rd quarter. Krensavage Asset Management LLC now owns 110,257 shares of the specialty pharmaceutical company’s stock valued at $12,284,000 after buying an additional 1,181 shares during the period. Two Sigma Advisers LP lifted its position in Jazz Pharmaceuticals by 393.0% in the third quarter. Two Sigma Advisers LP now owns 106,000 shares of the specialty pharmaceutical company’s stock worth $11,809,000 after buying an additional 84,500 shares during the last quarter. Stifel Financial Corp boosted its stake in Jazz Pharmaceuticals by 17.0% during the third quarter. Stifel Financial Corp now owns 142,075 shares of the specialty pharmaceutical company’s stock worth $15,829,000 after buying an additional 20,675 shares during the period. Finally, Systematic Financial Management LP increased its position in Jazz Pharmaceuticals by 11.7% during the third quarter. Systematic Financial Management LP now owns 283,977 shares of the specialty pharmaceutical company’s stock valued at $31,638,000 after acquiring an additional 29,647 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JAZZ shares. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $120.15 on Wednesday. The company has a market cap of $7.26 billion, a PE ratio of 16.92, a P/E/G ratio of 1.04 and a beta of 0.57. The firm’s 50 day moving average price is $116.59 and its 200-day moving average price is $111.85. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.